Genomic instability in multiple myeloma: Evidence for jumping segmental duplications of chromosome arm 1q

Genes Chromosomes and Cancer

Volumn 42, Issue 1, 2005, Pages 95-106

  Sawyer, Jeffrey R ^a,b   Tricot, Guido ^a   Lukacs, Janet L ^b   Binz, Regina Lichti ^b   Tian, Erming ^a   Barlogie, Bart ^a   Shaughnessy Jr , John ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME 1Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME ARM; CHROMOSOME BAND; CHROMOSOME DUPLICATION; CHROMOSOME INSERTION; CLINICAL ARTICLE; DNA SEQUENCE; FEMALE; GENE TRANSLOCATION; HUMAN; KARYOTYPE; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

ADULT; AGED; CHROMOSOME BANDING; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; GENE DUPLICATION; GENOMIC INSTABILITY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA;

INSERTION SEQUENCES;

EID: 9644289448     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20109     Document Type: Article

References (26)

1. Callanan MB, Le Baccon P, Mossuz P, Duley S, Bastard C, Hamoudi R, Dyer MJ, Klobeck G, Rimokh R, Sotto JJ, Leroux D. 2000. The IgG Fc receptor, FcgammaRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma. PNAS USA 97:309-314.
2. Chen W, Palanisamy N, Schmidt H, Teruya-Feldstein J, Jhanwar SC, Zeleneta AD, Houldsworth J, Chaganti RS. 2001. Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. Oncogene 20:7686-7693.
3. Dewald GW, Kyle RA, Hicks GA, Greipp PR. 1985. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia or amyloidosis. Blood 66:380-390.
4. Dyomin VG, Palanisamy N, Lloyd KO, Dyomina K, Jhanwar SC, Houldsworth J, Chaganti RS. 2000. MuC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood 95:2666-2671.
5. Fassas A, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E, Muwalla F, Morris C, Barlogie B, Tricot G. 2002. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Brit J Haematol 118:1-7.
6. Gilles F, Goy A, Remache Y, Shue P, Zelenetz AD. 2000. MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma. Blood 95:2930-2936.
7. Hallek M, Bergsagel PL, Anderson KC. 1998. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91:3-21.
8. Hatzivassiliou G, Miller I, Takizawa J, Palanismay N, Rao PH, Iida S, Tagawa S, Taniwaki M, Russo J, Neri A, Cattoretti G, Clynes R, Mendelsohn C, Chaganti RS, Dalla-Favera R. 2001. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 14:277-289.
9. ISCN. 1995. Guidelines for cancer cytogenetics, 1995. In: Mitelman F, editor. Supplement to an international system for human cytogenetic nomenclature. Basel, Switzerland: Karger.
10. Itoyama T, Nanjungud G, Chen W, Dyomin VG, Teruya-Feldstein J, Jhanwar SC, Zeleneta AD, Chaganti RS. 2002. Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer 35:318-328.
11. Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A, Zangari M, Girous D, Crowley J, Hough A, Sawyer J. 2003. MDS-type abnormalities with in myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Brit J Haematol 122:430-440.
12. Kuehl WM, Bergsagel PL. 2002. Multiple myeloma: Evolving genetic events and host interactions. Nat Rev Cancer 2:175-187.
13. Le Baccon P, Leroux D, Dascalescu C, Duley S, Marais D, Esmenjaud E, Sotto JJ, Callanan M. 2001. Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma. Genes Chromosomes Cancer 32:250-264.
14. Lestou VS, Gascoyne RD, Salski C, Connors JM, Horsman DE. 2002. Uncovering novel inter- and intrachromosomal chromosome 1 aberrations in follicular lymphomas by using an innovative multicolor banding technique. Genes Chromosomes Cancer 34:201-210.
15. Meza-Zepeda LA, Forus A, Lygren B, Dahlverg AB, Godager LH, South AP, Marenholz I, Lioumi M, Florenes VA, Maelandsmo GM, Serra M, Mischke D, Nizetic D, Ragoussis J, Tarkkanen M, Nesland JM, Knuutila S, Myklebost O. 2002. Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. Oncogene 21:2261-2269.
16. Padilla-Nash HM, Heselmeyer-Haddad K, Wangsa D, Zhang H, Ghadimi BM, Macville M, Augustus M, Schrock E, Hilgenfeld E, Reid T. 2001. Jumping translocations are common in solid tumor cell lines and result in recurrent fusions of whole chromosome arms. Genes Chromosomes Cancer 30:349-363.
17. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. 1995. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genetics Cytogenetics 82:41-49.
18. Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B. 1998a. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 91:1732-1741.
19. Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhal S, Mehta J, Siegel D, Shaughnessy J, Barlogie B. 1998b. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 92:4269-4278.
20. Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, Huh YM, Glassman A, Champlin R, Alexanian R. 1998. Prognostic value of cytogenetics in multiple myeloma. Brit J Haematol 101:189-194.
21. Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, DeWald G, Kirsch IR, Bergsagel PL, Kuehl WM. 2000. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. PNAS USA 97:228-233.
22. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. 2001. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98:2229-2239.
23. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR. 1995. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 88:4250-4256.
24. Willis TG, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, Jadayel DM, Bastard C, Treleaven JG, Catovsky D, Silva ML, Dyer MJ. 1998. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 91:1873-1881.
25. Wong N, Chan A, Lee SW, Lam E, To KF, Lai PB, Li XN, Liew CT, Johnson PJ. 2003. Positional mapping for amplified DNA sequences on 1q21-q22 in hepatocellular carcinoma indicates candidate gene over-expression. J Hepatol 38:298-306.
26. Zhan F, Tain E, Brumm K, Smith R, Barlogie B, Shaughnessy J Jr. 2003. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 101:1128-1140.